← All indications
Nephritis
Inflammation of any part of the KIDNEY.
Subtype terms (4)
More specific conditions that are subtypes of Nephritis in the MeSH hierarchy.
- Glomerulonephritis
64 drugs (44 approved, 20 experimental)
- Nephritis, Hereditary
19 drugs (11 approved, 8 experimental)
- Nephritis, Interstitial
- Pyelitis
Drugs by status
Phase 4 trials (3)
Phase 3 trials (2)
Phase 2 trials (8)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (30)
- Astellas
- Mallinckrodt
- Huazhong University of Science and Technology
- Aarhus University
- Central South University
- Case Western Reserve University
- Chulalongkorn University
- Cornell University
- Ohio State University
- The Rogosin Institute
- University of Southern Denmark
- Chinese University of Hong Kong
- Columbia University
- Fujian Medical University
- Nanchang University
- University of Cincinnati
- Shandong University
- Bangladesh Medical University
- Jiao Tong University
- Al Azhar University
- The University of Hong Kong
- Sun Yat-Sen University
- Jawaharlal Institute of Postgraduate Medical Education and Research
- Tuen Mun Hospital, Hong Kong
- Ningxia Medical University
- China Medical University
- The Cleveland Clinic
- The First People's Hospital of Yunan Province
- Berlin Pharmaceutical Industry Co., LTD.
- Region MidtJylland Denmark
Organization Involved with Phase 3 Indications (54)
- Human Genome Sciences
- Bristol-Myers Squibb
- Roche
- Merck Serono
- Genentech
- Novartis
- Anthera Pharmaceuticals
- Aurinia Pharmaceuticals Inc.
- GlaxoSmithKline
- La Jolla Pharmaceutical Company
- ZymoGenetics
- Medical University of Graz
- University of London
- Guangxi Medical University
- Guangzhou Medical University
- Hospital General Universitario Gregorio Marañon
- Hospital Infanta Sofia
- Hospital Universitario Fundación Alcorcón
- Radboud University
- Sichuan University
- Universidad Complutense de Madrid
- University of Groningen
- Peking University
- University of Cambridge
- Université catholique de Louvain
- Tsinghua University
- University of Vienna
- Leiden University
- Southern Medical University
- Karolinska Institute
- +24 more
Organization Involved with Phase 2 Indications (46)
- Immunomedics
- AstraZeneca
- Biogen
- Alexion
- BeOne Medicines
- Nippon Kayaku Co.,Ltd.
- Omeros Corporation
- Parexel
- Red de Terapia Celular
- Teva
- Apellis Pharmaceuticals, Inc.
- Boehringer Ingelheim
- Genovate Biotechnology Co., Ltd.,
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Henan University of Traditional Chinese Medicine
- Masaryk University
- Nanjing Medical University
- Nanjing University
- Organ Transplant Institute, China
- Palacky University
- Seoul National University
- University of Heidelberg
- Mayo Clinic
- Chitwan Medical College
- Fudan University
- University of California, San Francisco
- Feinstein Institute for Medical Research
- Department of Defense
- Taipei Veteran General hospital
- +16 more
Organization Involved with Phase 1 Indications (10)
Organization Involved with Other Experimental Indications (18)
- Changhai Hospital
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Mahidol University
- Northwell Health
- Siriraj Hospital
- Capital Medical University
- Prince of Songkla University
- Wenzhou Medical University
- Dalian Medical University
- Soochow University
- Anhui College of Traditional Chinese Medicine
- Maharaj Nakorn Chiang Mai Hospital
- Government of Mexico
- Rajavithi Hospital, Bangkok
- KhonKaen University
- Bengbu Medical College
- AnHui ShengLi Hospital
- Jinlin University